Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study of Lapatinib (Tyverb) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy.

Next Previous
Trial Profile

Pilot Study of Lapatinib (Tyverb) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy.

Status: Discontinued
Phase of Trial: Phase 0

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Bladder cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms LAPAINBLAD

Most Recent Events

  • 13 Jun 2012 Additional lead trial investigators (Thierry Lebret and Pascal Rischmann) identified as reported by ClinicalTrials.gov.
  • 13 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
  • 23 Nov 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top